Influenza B causes roughly half of all seasonal flu cases yet receives far less vaccine development attention than influenza A, leaving millions vulnerable to severe illness each winter. This research gap matters because influenza B hospitalizes patients at rates comparable to its more famous cousin, particularly affecting children and older adults who struggle to mount robust immune responses. Scientists have now identified a collection of broadly neutralizing antibodies that can disable multiple strains of influenza B through an unexpected dual mechanism. These antibodies simultaneously mimic the virus's natural cellular receptor while also binding to sugar molecules on the viral surface called glycans. This two-pronged attack effectively prevents the virus from attaching to and infecting human cells across diverse influenza B lineages. The antibodies demonstrated potent neutralizing activity against both major influenza B lineages—Victoria and Yamagata—suggesting they could provide protection against the unpredictable strain variations that make seasonal vaccines less effective. This dual-targeting approach represents a significant departure from traditional antibody strategies that typically focus on single viral components. The discovery could accelerate development of universal influenza B vaccines that provide broader, longer-lasting protection than current seasonal formulations. However, the research remains in early stages, conducted entirely in laboratory settings without human testing. The antibodies' safety profile, manufacturing scalability, and real-world effectiveness against circulating strains require extensive clinical validation. Most critically, whether this receptor-mimicry mechanism can be translated into practical vaccines or therapeutic treatments remains unproven. Still, the finding offers a promising new pathway for addressing influenza B's persistent threat to public health.